Engage Therapeutics is a biopharmaceutical company bringing innovative medicines to market. The Company's lead investigational drug is Staccato alprazolam, a small, easy-to-use hand-held drug-device combination product that leverages an FDA-approved delivery system with FDA-approved alprazolam for the cessation of active and acute epileptic seizures. Staccato alprazolam in a Phase 2a proof of concept study demonstrated reduction of seizure in a photosensitivity model. The product will proceed into an advanced clinical setting leveraging a 505(b)(2) regulatory pathway.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/27/17 | $23,000,000 | Series A |
Adage Capital Management LifeSci Venture Partners Lumira Capital TPG Biotech  | undisclosed |
